Europe Specialty Generics Market Size, Share & Industry Trends Analysis Report

Europe Specialty Generics Market Size, Share & Industry Trends Analysis Report By Type (Injectables, Oral Drugs, and Others), By Application, By End Use (Specialty Pharmacy, Retail Pharmacy, and Hospital Pharmacy), By Country and Growth Forecast, 2023 - 2030


The Europe Specialty Generics Market would witness market growth of 9.3% CAGR during the forecast period (2023-2030).

The market share is anticipated to increase due to factors like the increasing incidence of diseases and the rising number of patent expirations. Chronic diseases, like cardiovascular conditions, cancer, and arthritis, among others, have become more prevalent recently, placing a considerable load on people's healthcare spending. A major factor driving the market is the rising prevalence of complex chronic diseases like hepatitis C and the growing use of specialty generic medications.

The generic version of that drug is referred to as its "specialty generic," and the word "specialty generics" is the term used to describe those generic versions. Multiple sclerosis, cancer, and rheumatoid arthritis are examples of diseases that can be effectively treated with these pharmaceuticals. When compared to their branded counterparts, specialty generics are significantly less expensive due to the lower expenses associated with their development and marketing.

Since younger birth cohorts also exhibit declining populations, according to Destatis, 2020, adults over 65 also make up an increasing share of the overall population over time. From 15% in 1991 to 22% in 2019, it increased. The number of people who are very old and over 85 is growing especially quickly. In 1991, there were 1.2 million of them, and by 2019, there were 2.4 million. According to a UN assessment of France aging policy, France, like other European nations, is experiencing a steady and large rise in the population of senior people. In 2012, there were 15 million persons in France over the age of 60. In 2060, this number will increase to 24 million. It is anticipated that the market will grow as a result of the aging populations in these regional nations.

The Germany market dominated the Europe Specialty Generics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $8,947.8 million by 2030. The UK market is experiencing a CAGR of 8.4% during (2023 - 2030). Additionally, The France market would exhibit a CAGR of 10.1% during (2023 - 2030).

Based on Type, the market is segmented into Injectables, Oral Drugs, and Others. Based on Application, the market is segmented into Inflammatory conditions, Multiple sclerosis, Hepatitis C, Oncology, and Others. Based on End Use, the market is segmented into Specialty Pharmacy, Retail Pharmacy, and Hospital Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Novartis AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Dr. Reddy’s Laboratories Ltd., Mallinckrodt PLC, Bausch Health Companies, Inc., Viatris, Inc. and Apotex, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Injectables
  • Oral Drugs
  • Others
By Application
  • Inflammatory conditions
  • Multiple sclerosis
  • Hepatitis C
  • Oncology
  • Others
By End Use
  • Specialty Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Hikma Pharmaceuticals PLC
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius SE & Co. KGaA
  • Dr. Reddy’s Laboratories Ltd.
  • Mallinckrodt PLC
  • Bausch Health Companies, Inc.
  • Viatris, Inc.
  • Apotex, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Specialty Generics Market, by Type
1.4.2 Europe Specialty Generics Market, by Application
1.4.3 Europe Specialty Generics Market, by End Use
1.4.4 Europe Specialty Generics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions: 2020, May – 2023, Jan) Leading Players
Chapter 4. Europe Specialty Generics Market by Type
4.1 Europe Injectables Market by Country
4.2 Europe Oral Drugs Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Specialty Generics Market by Application
5.1 Europe Inflammatory conditions Market by Country
5.2 Europe Multiple sclerosis Market by Country
5.3 Europe Hepatitis C Market by Country
5.4 Europe Oncology Market by Country
5.5 Europe Others Market by Country
Chapter 6. Europe Specialty Generics Market by End Use
6.1 Europe Specialty Pharmacy Market by Country
6.2 Europe Retail Pharmacy Market by Country
6.3 Europe Hospital Pharmacy Market by Country
Chapter 7. Europe Specialty Generics Market by Country
7.1 Germany Specialty Generics Market
7.1.1 Germany Specialty Generics Market by Type
7.1.2 Germany Specialty Generics Market by Application
7.1.3 Germany Specialty Generics Market by End Use
7.2 UK Specialty Generics Market
7.2.1 UK Specialty Generics Market by Type
7.2.2 UK Specialty Generics Market by Application
7.2.3 UK Specialty Generics Market by End Use
7.3 France Specialty Generics Market
7.3.1 France Specialty Generics Market by Type
7.3.2 France Specialty Generics Market by Application
7.3.3 France Specialty Generics Market by End Use
7.4 Russia Specialty Generics Market
7.4.1 Russia Specialty Generics Market by Type
7.4.2 Russia Specialty Generics Market by Application
7.4.3 Russia Specialty Generics Market by End Use
7.5 Spain Specialty Generics Market
7.5.1 Spain Specialty Generics Market by Type
7.5.2 Spain Specialty Generics Market by Application
7.5.3 Spain Specialty Generics Market by End Use
7.6 Italy Specialty Generics Market
7.6.1 Italy Specialty Generics Market by Type
7.6.2 Italy Specialty Generics Market by Application
7.6.3 Italy Specialty Generics Market by End Use
7.7 Rest of Europe Specialty Generics Market
7.7.1 Rest of Europe Specialty Generics Market by Type
7.7.2 Rest of Europe Specialty Generics Market by Application
7.7.3 Rest of Europe Specialty Generics Market by End Use
Chapter 8. Company Profiles
8.1 Teva Pharmaceutical Industries Ltd.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Product Launches and Product Expansions:
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expense
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 Hikma Pharmaceuticals PLC
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Sun Pharmaceutical Industries Ltd.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.5 Fresenius SE & Co. KGaA
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Acquisition and Mergers:
8.6 Dr. Reddy’s Laboratories Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.7 Mallinckrodt PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.8 Bausch Health Companies, Inc
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.9 Viatris, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.10. Apotex, Inc.
8.10.1 Company Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings